PML nuclear bodies orchestrate antiviral response in HBV-infected hepatocytes

abstract in conference proceedings
Creative Commons License IconCreative Commons BY Icon
Thumbnail
File can be accessed.Get publication
Author
Janovec, VáclavORCiD Profile - 0000-0002-6262-3364WoS Profile - N-7608-2017Scopus Profile - 57193086112
Rjabčenko, BorisORCiD Profile - 0000-0001-7076-256XWoS Profile - U-8964-2017Scopus Profile - 36142246600
Lubyová, Barbora
Huerfano Meneses, SandraORCiD Profile - 0000-0001-5221-3014WoS Profile - G-8469-2013Scopus Profile - 6506988916
Weber, Jan
Hirsch, IvanORCiD Profile - 0000-0003-1701-1438WoS Profile - R-3103-2016Scopus Profile - 56275056800
Grantz Šašková, KláraORCiD Profile - 0000-0003-2874-5699WoS Profile - E-1931-2014Scopus Profile - 22954587000
Šímová, Šárka

Publication date
2023
Published in
Czech Chemical Society Symposium Series
Volume / Issue
21 (5)
ISBN / ISSN
ISSN: 2336-7202
Metadata
Show full item record
Collections
Abstract
Promyelocytic leukaemia nuclear bodies (PML-NBs) play roles in various cellular functions and represent a key component of antiviral defense. In the case of hepatitis B virus (HBV), the antiviral activity of PML-NBs has been associated with the presence of SMC5/6 and epigenetic silencing of cccDNA. However, PML-NBs can have apleiotropic effect on the life cycle of HBV and the role of PML-NBs needs to be further elucidated.
Keywords
PML-NBs, HepG2-NTCP
Permanent link
https://hdl.handle.net/20.500.14178/2067
License

Full text of this result is licensed under: Creative Commons Uveďte původ 4.0 International

Show license terms